Allspring Global Investments Holdings LLC Has $25.59 Million Stock Holdings in Ascendis Pharma A/S (NASDAQ:ASND)

Allspring Global Investments Holdings LLC trimmed its position in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 4.6% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 203,172 shares of the biotechnology company's stock after selling 9,823 shares during the period. Allspring Global Investments Holdings LLC owned about 0.35% of Ascendis Pharma A/S worth $25,589,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in ASND. Coppell Advisory Solutions LLC purchased a new position in Ascendis Pharma A/S in the second quarter valued at approximately $45,000. SkyView Investment Advisors LLC acquired a new stake in shares of Ascendis Pharma A/S in the second quarter valued at approximately $66,000. BNP Paribas Arbitrage SA acquired a new stake in shares of Ascendis Pharma A/S in the second quarter valued at approximately $67,000. Signaturefd LLC boosted its holdings in shares of Ascendis Pharma A/S by 31.9% in the third quarter. Signaturefd LLC now owns 798 shares of the biotechnology company's stock valued at $75,000 after acquiring an additional 193 shares during the period. Finally, Legal & General Group Plc acquired a new stake in shares of Ascendis Pharma A/S in the third quarter valued at approximately $97,000.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on ASND. Wells Fargo & Company increased their price objective on Ascendis Pharma A/S from $196.00 to $260.00 and gave the company an "overweight" rating in a report on Friday, March 15th. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $173.00 price target on shares of Ascendis Pharma A/S in a report on Monday, April 1st. StockNews.com raised Ascendis Pharma A/S from a "sell" rating to a "hold" rating in a report on Monday, December 25th. Citigroup increased their price target on Ascendis Pharma A/S from $146.00 to $182.00 and gave the stock a "buy" rating in a report on Thursday, February 8th. Finally, JPMorgan Chase & Co. increased their price target on Ascendis Pharma A/S from $165.00 to $167.00 and gave the stock an "overweight" rating in a report on Tuesday, April 2nd. Two research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $173.25.

Ascendis Pharma A/S Stock Down 3.3 %

Shares of Ascendis Pharma A/S stock traded down $5.00 on Friday, hitting $146.04. 318,762 shares of the company's stock traded hands, compared to its average volume of 292,286. The stock has a market cap of $8.50 billion, a P/E ratio of -15.79 and a beta of 0.50. The firm's 50-day moving average is $149.06 and its 200 day moving average is $122.93. Ascendis Pharma A/S has a 52-week low of $66.03 and a 52-week high of $161.00.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last posted its quarterly earnings results on Wednesday, February 7th. The biotechnology company reported ($1.66) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.15) by $0.49. Ascendis Pharma A/S had a negative return on equity of 16,574.15% and a negative net margin of 180.61%. The business had revenue of $148.62 million for the quarter, compared to analyst estimates of $97.02 million. Equities research analysts forecast that Ascendis Pharma A/S will post -4.18 EPS for the current year.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.